Guardant Health, Inc. reported significant financial results for the second quarter of 2026, with total revenue reaching $335.0 million, a 44% increase from $232.1 million in the same period last year. For the first half of 2026, revenue totaled $636.6 million, up 46% from $435.6 million in the first half of 2025. The growth was primarily driven by increased demand for the company's oncology and screening tests, particularly the Guardant360 and Shield tests. However, the company also reported a net loss of $120.1 million for the second quarter, compared to a loss of $99.9 million in the prior year, and a total net loss of $232.2 million for the first half of 2026, up from $195.1 million in the same period of 2025.
The company's operating expenses increased significantly, with total costs and operating expenses for the second quarter amounting to $464.1 million, compared to $338.5 million in the prior year. This increase was attributed to higher costs in research and development, sales and marketing, and general and administrative expenses. Notably, sales and marketing expenses surged by 59% to $190.0 million, reflecting the company's investment in expanding its commercial infrastructure and marketing efforts to support growth in its oncology and screening segments.
Guardant Health's operational metrics also showed promising trends, with oncology test volumes increasing to approximately 104,000 in the second quarter of 2026, up from 64,000 in the same quarter of 2025. The company also reported a substantial increase in screening revenue, which rose by 257% to $52.9 million, driven by a rise in Shield screening test volumes. The company continues to expand its product offerings, having received FDA approval for its Guardant360 Liquid CDx test in the second quarter, which integrates genomic and epigenomic insights.
As of June 30, 2026, Guardant Health had cash, cash equivalents, and restricted cash totaling approximately $1.2 billion, a significant increase from $735.5 million at the end of 2025. This liquidity positions the company well to support its ongoing investments in research and development and to expand its market presence. The company anticipates continued growth in revenue driven by increased adoption of its tests and expansion into new markets, including international opportunities. However, it also acknowledges the potential risks associated with reimbursement rates and market conditions that could impact future performance.
About Guardant Health, Inc.
Guardant Health, Inc. is a precision oncology company providing blood and tissue tests for cancer detection, monitoring, and therapy selection. Its core offerings include liquid biopsies, early detection screens, and companion diagnostics, serving patients, clinicians, and biopharmaceuticals globally. The company leverages advanced sequencing, AI, and real-world data to improve cancer outcomes and supports drug development and research through its comprehensive testing platform.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov